Emagine Solutions Technology Secures ACA Grant, Launches Applications for Arizona Maternal Health Study
Emagine Solutions Technology, a company focused on advancing maternal health through innovative digital and wearable solutions, has announced that it has been awarded a significant $250,000 grant by the Arizona Commerce Authority (ACA). This funding comes through the ACA’s WearTech Applied Research Center, a program dedicated to accelerating the development and validation of next-generation technologies in healthcare, biomedical science, and related fields. The grant represents a major milestone for Emagine as it continues to expand its research and impact in the maternal health space.
The WearTech Applied Research Center, established in 2019, has played a pivotal role in supporting emerging technologies by helping reduce the risks associated with early-stage innovation. By partnering with leading Arizona universities, the center has enabled numerous projects to move from concept to real-world application. Its mission centers on fostering advancements that can transform healthcare delivery, improve patient outcomes, and create scalable solutions for future challenges. Through this initiative, Emagine Solutions Technology joins a growing list of organizations working at the intersection of healthcare and wearable technology.
With the support of this grant, Emagine will collaborate closely with The Preeclampsia Foundation, a well-known nonprofit organization dedicated to improving the outcomes of hypertensive disorders in pregnancy. Together, they will conduct an in-depth research study aimed at understanding how wearable devices and digital health tools can influence pregnancy care and maternal outcomes. This partnership underscores a shared commitment to addressing critical gaps in maternal healthcare, particularly in areas such as hypertension and preeclampsia, which continue to pose serious risks to pregnant individuals.
At the core of this initiative is a groundbreaking maternal health study designed to evaluate how technology can be integrated into everyday pregnancy care. Emagine is actively seeking participants for this study, inviting eligible individuals across Arizona to contribute to research that could shape the future of maternal health. The study will be conducted under the guidance of Dr. Sharon Thompson, an OB-GYN who serves as the Science and Technology Advisor for Emagine. Her clinical expertise and leadership will help ensure that the research is both medically sound and patient-centered.
The study will utilize several innovative tools, including The Journey Pregnancy app, a digital platform developed to support expectant mothers throughout their pregnancy journey. Participants will also use Preeclampsia Foundation Cuff Kits, which are designed to enable at-home blood pressure monitoring—an essential component in identifying and managing hypertensive conditions during pregnancy. In addition, wearable fitness tracking technology will be incorporated to gather real-time data on physical activity, heart rate, and other health indicators.
To be eligible for participation, individuals must meet a few key criteria. Participants must be at least 18 years of age, currently pregnant, and residing in the state of Arizona. These requirements ensure that the study focuses on a specific population while maintaining the integrity and relevance of the data collected.
Emagine is offering several incentives to encourage participation and recognize the valuable contribution of study volunteers. Upon completing the study, participants will receive a $50 gift card as a token of appreciation. They will also be provided with a complimentary blood pressure monitoring kit from The Preeclampsia Foundation, which includes an iHealth blood pressure monitor. This device allows participants to track their blood pressure conveniently from home, promoting proactive health management. Additionally, participants will receive a Fitbit Charge 6 Premium Fitness Tracker at no cost, enabling continuous monitoring of key health metrics throughout their pregnancy.
The research will focus on several important areas. One of the primary objectives is to explore how participants perceive and interact with health tracking technologies during pregnancy and the early postpartum period. Understanding user experience is critical, as it can influence adherence, engagement, and ultimately the effectiveness of these tools in real-world settings.
Another key area of investigation is the feasibility of using a combination of digital and wearable technologies during pregnancy. This includes assessing how well participants can incorporate devices such as home blood pressure monitors and fitness trackers into their daily routines, as well as how effectively the Journey Pregnancy app supports their health management. By evaluating these factors, researchers aim to determine whether such technologies can be scaled and integrated into standard prenatal care practices.
The study also seeks to generate valuable data on maternal health trends, particularly in relation to hypertension and preeclampsia. These conditions are among the leading causes of complications during pregnancy and can have long-term health implications for both the mother and the baby. Early detection and consistent monitoring are essential for managing these risks, and wearable technology may offer a practical solution for achieving this.
According to data from The Commonwealth Fund, Arizona currently ranks 44th out of 51 states in terms of maternal health outcomes. This statistic highlights a pressing need for innovative approaches to improve care and reduce disparities. Emagine’s research aims to address this challenge by leveraging technology to enhance monitoring, increase patient engagement, and provide actionable insights for healthcare providers.
Courtney Williams, Co-founder and CEO of Emagine Solutions Technology, emphasized the importance of this initiative and its potential impact. She noted that hypertension, including conditions like preeclampsia, remains a critical area of concern in maternal health. Women who experience preeclampsia during pregnancy are significantly more likely—by as much as three to four times—to develop cardiovascular issues later in life. This underscores the need for early intervention and ongoing monitoring, both during and after pregnancy.
Williams also highlighted the broader vision behind the study, which is to gather meaningful data and feedback that can inform the development of more effective healthcare solutions. By understanding how patients use and respond to technology, Emagine hopes to refine its tools and contribute to a more proactive, personalized approach to pregnancy care. The ultimate goal is to make maternal healthcare safer, more accessible, and more cost-effective, while improving outcomes for mothers and their babies.
In conclusion, the ACA grant represents a significant opportunity for Emagine Solutions Technology to advance its mission and drive meaningful change in maternal health. Through its collaborative research study, the company aims to demonstrate how wearable devices and digital health platforms can play a transformative role in pregnancy care. By engaging participants across Arizona and focusing on real-world applications, this initiative has the potential to generate insights that could benefit not only the local community but also the broader healthcare landscape.
About Emagine Solutions Technology
An award-winning healthcare technology company, Emagine is your companion for a safe pregnancy. We are tackling the U.S. maternal health crisis with AI-driven remote patient monitoring software for better outcomes
